A prospective dose–response analysis of total daily steps with all-cause mortality and incident cardiovascular disease (CVD) by sedentary time levels revealed that any number of daily steps above 2200 steps/day was associated with lower mortality and incident CVD risk, with 9000–10 500 steps/day being associated with the lowest mortality risk independent of sedentary time. The analysis included 72 174 UK participants (age=61.1±7.8 years), 1633 deaths and 6190 CVD events over 6.9 (±0.8) years of follow-up. Compared with the referent 2200 steps/day (5th percentile), the optimal dose for all-cause mortality ranged between 9000 and 10 500 steps/day for high (≥10.5 hours/day, HR 0.61) and low (<10.5 hours/day, HR 0.69) sedentary time. For incident CVD, there was a subtle gradient of association by sedentary time level with the lowest risk observed at approximately 9700 steps/day for high (HR 0.79) and low (HR 0.71) sedentary time. For a roughly equivalent number of steps/day, the risk of incident CVD was lower for low sedentary time compared with high sedentary time. The minimal dose (50% of the optimal dose) of daily steps was between 4000 and 4500 steps/day across sedentary time groups for all-cause mortality and incident CVD. The findings provide tangible targets and new insights regarding the dose response of daily steps, sedentary time, mortality, and CVD risk. Source: https://bjsm.bmj.com/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.